Pharmaceutical composition containing imidazoline derivative
AssigneeJiangsu Hengrui Medicine Co., Ltd.
InventorsYun Lu, Xinhua Zhang, Daimei Zhang
Life of this patent
Estimating the term…
Abstract
Provided in the present invention is a pharmaceutical composition containing an imidazoline derivative. In particular, the pharmaceutical composition provided in the present invention contains (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile and cellulose ether; and the composition has a good stability, dissolution rate and bioavailability.
Claims19
A pharmaceutical composition, comprising (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile, and a cellulose ether.
A pharmaceutical composition, comprising:
- 1) 5%-50% by weight of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-l-yl)-2-(trifluoromethyl)benzonitrile;
- 2) 0.5%-10% by weight of hydroxypropyl cellulose;
- 3) 40-80% by weight of a filler, wherein the filler comprises a mixture of lactose and microcrystalline cellulose;
- 4) 3%-20% by weight of a disintegrant, wherein the disintegrant comprises one or more selected from the group consisting of croscarmellose sodium and sodium carboxymethyl starch;
- and 5) 0.1-2% by weight of a lubricant, wherein the lubricant comprises one or more selected from the group consisting of magnesium stearate, stearic acid, and glyceryl behenate.
Dependencies are inferred from the claim text.